Skip to main content

Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid

Author(s): Asam, Kesava; Staniszewski, Agnieszka; Zhang, Hong; Melideo, Scott L; Mazzeo, Adolfo; et al

Download
To refer to this page use: http://arks.princeton.edu/ark:/88435/pr1pg1hn28
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAsam, Kesava-
dc.contributor.authorStaniszewski, Agnieszka-
dc.contributor.authorZhang, Hong-
dc.contributor.authorMelideo, Scott L-
dc.contributor.authorMazzeo, Adolfo-
dc.contributor.authorVoronkov, Michael-
dc.contributor.authorHuber, Kristen L-
dc.contributor.authorPérez, Eduardo-
dc.contributor.authorStock, Maxwell-
dc.contributor.authorStock, Jeffry B-
dc.contributor.authorArancio, Ottavio-
dc.contributor.authorNicholls, Russell E-
dc.date.accessioned2022-01-25T14:51:19Z-
dc.date.available2022-01-25T14:51:19Z-
dc.date.issued2017-12-18en_US
dc.identifier.citationAsam, Kesava, Staniszewski, Agnieszka, Zhang, Hong, Melideo, Scott L, Mazzeo, Adolfo, Voronkov, Michael, Huber, Kristen L, Pérez, Eduardo, Stock, Maxwell, Stock, Jeffry B, Arancio, Ottavio, Nicholls, Russell E. (2017). Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. PloS one, 12 (12), e0189413 - ?. doi:10.1371/journal.pone.0189413en_US
dc.identifier.issn1932-6203-
dc.identifier.urihttp://arks.princeton.edu/ark:/88435/pr1pg1hn28-
dc.description.abstractSoluble forms of oligomeric beta-amyloid (Aβ) are thought to play a central role in Alzheimer's disease (AD). Transgenic manipulation of methylation of the serine/threonine protein phosphatase, PP2A, was recently shown to alter the sensitivity of mice to AD-related impairments resulting from acute exposure to elevated levels of Aβ. In addition, eicosanoyl-5-hydroxytryptamide (EHT), a naturally occurring component from coffee beans that modulates PP2A methylation, was shown to confer therapeutic benefits in rodent models of AD and Parkinson's disease. Here, we tested the hypothesis that EHT protects animals from the pathological effects of exposure to elevated levels of soluble oligomeric Aβ. We treated mice with EHT-containing food at two different doses and assessed the sensitivity of these animals to Aβ-induced behavioral and electrophysiological impairments. We found that EHT administration protected animals from Aβ-induced cognitive impairments in both a radial-arm water maze and contextual fear conditioning task. We also found that both chronic and acute EHT administration prevented Aβ-induced impairments in long-term potentiation. These data add to the accumulating evidence suggesting that interventions with pharmacological agents, such as EHT, that target PP2A activity may be therapeutically beneficial for AD and other neurological conditions.en_US
dc.format.extente0189413 - e0189413en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofPloS Oneen_US
dc.rightsFinal published version. This is an open access article.en_US
dc.titleEicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloiden_US
dc.typeJournal Articleen_US
dc.identifier.doidoi:10.1371/journal.pone.0189413-
dc.identifier.eissn1932-6203-
pu.type.symplectichttp://www.symplectic.co.uk/publications/atom-terms/1.0/journal-articleen_US

Files in This Item:
File Description SizeFormat 
Eicosanoyl_5_hydroxytryptamide_Alzheimer's_beta_amyloid.pdf3.84 MBAdobe PDFView/Download


Items in OAR@Princeton are protected by copyright, with all rights reserved, unless otherwise indicated.